deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT06021990

Clopidogrel for the Prevention of Exacerbations in Severe COPD (CLOPEX)

Role of Clopidogrel in Preventing Exacerbations in Patients With Severe COPD: An Open-label Randomized Controlled Trial.

Sponsor: Lady Reading Hospital, Pakistan

Conditions COPD COPD Exacerbation Acute
Interventions Clopidogrel Bisulfate 75Mg Tab
Updated 5 times since 2023 Last updated: Oct 2, 2023 Started: Oct 1, 2023 Primary completion: Sep 30, 2024 Completion: Dec 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates COPD and COPD Exacerbation Acute and is currently ongoing. Lady Reading Hospital, Pakistan leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2025 · 15 months · monthly snapshotRecruiting~Dec 2025 – present · 7 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Dec 2025 — Present [monthly]

    Unknown PHASE3

    Status: Recruiting → Unknown

  2. Sep 2024 — Dec 2025 [monthly]

    Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  4. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  5. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lady Reading Hospital, Pakistan
  • Pakistan Chest Society, Pakistan
Data source: Lady Reading Hospital, Pakistan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations